6299-87-2

Usage

Uses

Used in Pharmaceutical Industry:
6-Oxo-3H-pyrimidine-4-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs. Its role in organic synthesis allows for the creation of compounds with potential therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 6-Oxo-3H-pyrimidine-4-carboxylic acid is utilized as a precursor in the production of agrochemicals, which can help in the development of pesticides and other agricultural chemicals to protect crops and enhance yield.
Used in Antiviral and Antibacterial Research:
6-Oxo-3H-pyrimidine-4-carboxylic acid is employed as a subject of study in antiviral and antibacterial research due to its potential properties that could lead to the development of new treatments and preventive measures against viral and bacterial infections.

InChI:InChI=1/C5H4N2O3/c8-4-1-3(5(9)10)6-2-7-4/h1-2H,(H,9,10)(H,6,7,8)

Upstream product

• 81333-07-5 6-amino-pyrimidine-4-carboxylic acid amide 
• 16953-49-4 6-diethoxymethyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one 
• 3473-63-0 formamidine acetic acid 
• 200116-47-8 sodium (E)-1,4-diethoxy-1,4-dioxobut-2-en-2-olate 
• 6313-33-3 formamidine hydrochloride 
• 40876-98-0 sodium 1,4-diethoxy-1,4-dioxobut-2-en-2-olate 
• 88330-76-1 diethyl oxalacetate sodium salt 
• 98841-44-2 6-diethoxymethyl-3H-pyrimidin-4-one 

Downstream Products

• 263270-52-6 6-chloropyrimidine-4-carbonyl chloride 
• 37131-91-2 6-chloropyrimidine-4-carboxylic acid 
• 1208980-46-4 6-chloro-N-(4-fluorophenyl)pyrimidine-4-carboxamide 
• 1146733-06-3 (6-chloro-pyrimidin-4-yl)-(3,4-dichloro-phenyl)-methanone 
• 1146733-07-4 (6-chloro-pyrimidin-4-yl)-(3,4-dimethyl-phenyl)-methanone 
• 1146733-08-5 (6-chloro-pyrimidin-4-yl)-(3,4-diethyl-phenyl)-methanone 
• 1146733-09-6 (6-chloro-pyrimidin-4-yl)-(3,4,5-trimethyl-phenyl)-methanone 
• 1146733-11-0 (4-benzyloxy-3,5-dimethyl-phenyl)-(6-chloro-pyrimidin-4-yl)-methanone 
• 1146733-10-9 3-{1-[6-(4-benzyloxy-3,5-dimethyl-benzoyl)-pyrimidin-4-yl]-piperidin-4-yl}-7-methoxy-1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one 
• 1146733-13-2 1-{1-[6-(4-benzyloxy-3,5-dimethyl-benzoyl)-pyrimidin-4-yl]-piperidin-4-yl}-1,3-dihydro-imidazo[4,5-b]pyridin-2-one 
• 1146730-92-8 4-methyl-6-{6-[4-(5-oxo-3-phenyl-4,5-dihydro-1,2,4-triazol-1-yl)-piperidin-1-yl]-pyrimidine-4-carbonyl}-3H-benzoxazol-2-one 
• 1146731-09-0 1-{1-[6-(3,4-dimethyl-benzoyl)-pyrimidin-4-yl]-piperidin-4-yl}-1,3-dihydro-imidazo[4,5-b]-pyridin-2-one 
• 1146731-12-5 1-{1-[6-(3,4-diethyl-benzoyl)-pyrimidin-4-yl]-piperidin-4-yl}-1,3-dihydro-imidazo[4,5-b]-pyridin-2-one 
• 1146731-15-8 3-[1-(6-benzoyl-pyrimidin-4-yl)-piperidin-4-yl]-7-methoxy-1,3,4,5-tetrahydro-benzo[d]-[1,3]diazepin-2-one 

Relevant academic research and scientific papers

Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists

The important roles of the CXCL12/CXCR4 axis in numerous pathogenic pathways involving HIV infection and cancer metastasis make the CXCR4 receptor an attractive target for the development of therapeutic agents. Through scaffold hybridization of a few known CXCR4 antagonists, a series of novel aminopyrimidine derivatives was developed. Compound 3 from this new scaffold demonstrates excellent binding affinity with CXCR4 receptor (IC50 = 54 nM) and inhibits CXCL12 induced cytosolic calcium increase (IC50 = 2.3 nM). Furthermore, compound 3 possesses good physicochemical properties (MW 353, clogP 2.0, PSA 48, pKa 6.7) and exhibits minimal hERG and CYP isozyme (e.g. 3A4, 2D6) inhibition. Collectively, these results strongly support further optimization of this novel scaffold to develop better CXCR4 antagonists.

CRYSTALLINE SALTS OF (S)-6-((1-ACETYLPIPERIDIN-4-YL)AMINO)-N-(3-(3,4-DIHYDROISOQUINOLIN-2(1H)-YL)-2-HYDROXYPROPYL)PYRIMIDINE-4-CARBOXAMIDE

Disclosed are novel crystalline salts of (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide and pharmaceutical compositions containing the same. Also disclosed are processes for the prepar

NOVEL COMPOUNDS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as in the description, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

CGRP ANTAGONISTS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

CGRP ANTAGONISTS

The present invention relates to novel CGRP antagonists of the general formula (I) in which U, V, X, Y, R1, R2, R3 are defined as described below, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts thereof, and the hydrates of the salts, particularly the physiologically compatible salts thereof having inorganic or organic acids or bases, pharmaceuticals comprising said compounds, the use thereof, and the method for the production thereof.

NOVEL COMPOUNDS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Compounds of formula (I): wherein R1, L2, R2, L3, R3, L4 and R4 are as defined herein, upregulate endogenous utrophin in predictive screens, and thus, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.

SOLUBILIZED THIAZOLOPYRIDINES

Provided herein are novel sirtuin-modulating compounds Structural Formula (I): and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

MGluR5 modulators V

The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS

The present invention relates to benzimidazole carboxamides of formula (I), the use of the compounds of formula (I) as inhibitors of as inhibitors of one or more kinases, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. Accordingly, the compound of Formula (I) or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by one or more kinase phathways, preferably by the raf kinase pathway, especially cancers.